DEA
| HOME | PRIVACY POLICY | CONTACT US | SITE DIRECTORY |
Skip Navigation

Global News Local News

 News from DEA
   News Releases
   Speeches & Testimony
   Photo Library
   Audio/Video Library
   FOIA

 Briefs & Background
 Drug Trafficking & Abuse
   Drug Information
   Prescription Drug Info.
   Drug Trafficking
   State Factsheets
 Law Enforcement
   Recent Cases
   Major Operations
   Intelligence Reports
   DEA Fugitives
   Training Opportunities
   Statistics
 Drug Policy
   Controlled Substances Act
   Federal Trafficking Penalties
   Drug Scheduling
 DEA Resources
   For Contractors
   For Job Applicants
   For Law Enforcement
   For Legislators
   For Parents & Teachers
   For Physicians/Registrants
   For Students
   For Victims of Crime

 Inside the DEA
   DEA's Mission
   DEA Leadership
   Programs & Operations
   Publications Library
   DEA Museum
   Staffing & Budget
   Office Locations
   DEA History
   DEA Wall of Honor
   Office of Diversion
   Acquisitions & Contracts
   DOJ Homepage


[print friendly page]

Morphine

Morphine is the principal constituent of opium and can range in concentration from 4 to 21 percent. Commercial opium is standardized to contain 10-percent morphine. In the United States, a small percentage of the morphine obtained from opium is used directly (about 15 tons): the remaining is converted to codeine and other derivatives (about 120 tons). Morphine is one of the most effective drugs known for the relief of severe pain and remains the standard against which new analgesics are measured. Like most narcotics, the use of morphine has increased significantly in recent years. Since 1990, there has been about a 3-fold increase in morphine products in the United States.

Morphine is marketed under generic and brand name products including "MS-Contin®," Oramorph SR®," MSIR®," Roxanol®," Kadian®," and RMS®." Morphine is used parenterally (by injection) for preoperative sedation, as a supplement to anesthesia, and for analgesia. It is the drug of choice for relieving pain of myocardial infarction and for its cardiovascular effects in the treatment of acute pulmonary edema. Traditionally; morphine was almost exclusively used by injection. Today, morphine is marketed in a variety of forms, including oral solutions, immediate and sustained-release tablets and capsules, suppositories, and injectable preparations. In addition, the availability of high-concentration morphine preparations (i.e., 20-mg/ml oral solutions, 25-mg/ml injectable solutions, and 200-mg sustained-release tablets) partially reflects the use of this substance for chronic pain management in opiate-tolerant patients.

 
www.dea.gov